Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chlamydia and non-specific urethritis.

J W Segura, T F Smith, L A Weed

    The Journal of Urology
    |June 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Carcinoma in Situ of the Bladder.

    Cancer·2018
    Same author

    Histoplasmosis in infancy; report of a case in an infant with a brief clinicopathologic review.

    Proceedings of the staff meetings. Mayo Clinic·2010
    Same author

    Budding in the tissue phase of the life cycle of Coccidioides immitis; preliminary report.

    Proceedings of the staff meetings. Mayo Clinic·2010
    Same author

    Histoplasmosis in infancy; the pathologic picture as seen in one case.

    Archives of pathology·2010
    Same author

    Ureteroscopic treatment of upper tract urinary calculi.

    Minerva urologica e nefrologica = The Italian journal of urology and nephrology·2005
    Same author

    Endourological management of upper tract transitional cell carcinoma.

    BJU international·2003
    Same journal

    On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

    The Journal of urology·2026
    Same journal

    Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

    The Journal of urology·2026
    Same journal

    Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

    The Journal of urology·2026
    Same journal

    The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

    The Journal of urology·2026
    Same journal

    Let's Shift the Focus from Death to Life after Fournier's Gangrene.

    The Journal of urology·2026
    Same journal

    Endourology and Nephrolithiasis.

    The Journal of urology·2026
    See all related articles

    Chlamydia trachomatis caused 42% of non-specific urethritis cases, transmitted sexually. Tetracycline is the recommended treatment for this common sexually transmitted infection.

    Area of Science:

    • Urology
    • Microbiology
    • Infectious Diseases

    Background:

    • Non-specific urethritis (NSU) is a common condition affecting men.
    • The causative agent of NSU has historically been difficult to identify.
    • Chlamydia trachomatis is a known sexually transmitted pathogen.

    Purpose of the Study:

    • To determine the prevalence of Chlamydia organisms in patients with non-specific urethritis.
    • To establish the likely role of Chlamydia in causing NSU.
    • To recommend appropriate treatment for Chlamydia-induced NSU.

    Main Methods:

    • Microbiological examination of urethral samples from patients with NSU.
    • Correlation of Chlamydia detection with clinical diagnosis of NSU.

    Related Experiment Videos

    Main Results:

    • Chlamydia organisms were identified in 42% of patients presenting with non-specific urethritis.
    • The presence of Chlamydia strongly suggests it as the etiological agent for the observed urethritis.
    • Sexual contact was identified as the mode of transmission.

    Conclusions:

    • Chlamydia trachomatis is a significant cause of non-specific urethritis.
    • Early diagnosis and treatment of Chlamydia are crucial for managing NSU.
    • Tetracycline, administered at 500 mg every 6 hours for 10 days, is the drug of choice for treating Chlamydia-related urethritis.